DK2901341T3 - Identifikation af tumorbeskyttelsesepitoper til behandling af cancere - Google Patents

Identifikation af tumorbeskyttelsesepitoper til behandling af cancere Download PDF

Info

Publication number
DK2901341T3
DK2901341T3 DK13840946.1T DK13840946T DK2901341T3 DK 2901341 T3 DK2901341 T3 DK 2901341T3 DK 13840946 T DK13840946 T DK 13840946T DK 2901341 T3 DK2901341 T3 DK 2901341T3
Authority
DK
Denmark
Prior art keywords
epitopes
identification
cancer treatment
tumor protection
tumor
Prior art date
Application number
DK13840946.1T
Other languages
English (en)
Inventor
Pramod K Srivastava
Ion Mandoiu
Fei Duan
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Application granted granted Critical
Publication of DK2901341T3 publication Critical patent/DK2901341T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK13840946.1T 2012-09-28 2013-09-27 Identifikation af tumorbeskyttelsesepitoper til behandling af cancere DK2901341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261707295P 2012-09-28 2012-09-28
PCT/US2013/062100 WO2014052707A2 (en) 2012-09-28 2013-09-27 Identification of tumor-protective epitopes for the treatment of cancers

Publications (1)

Publication Number Publication Date
DK2901341T3 true DK2901341T3 (da) 2019-07-15

Family

ID=50389139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13840946.1T DK2901341T3 (da) 2012-09-28 2013-09-27 Identifikation af tumorbeskyttelsesepitoper til behandling af cancere

Country Status (9)

Country Link
US (2) US10501801B2 (da)
EP (1) EP2901341B1 (da)
JP (2) JP6501708B2 (da)
AU (2) AU2013323368B2 (da)
DK (1) DK2901341T3 (da)
ES (1) ES2737757T3 (da)
HR (1) HRP20191182T1 (da)
LT (1) LT2901341T (da)
WO (1) WO2014052707A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2901341T (lt) 2012-09-28 2019-09-25 The University Of Connecticut Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui
WO2015153991A1 (en) * 2014-04-04 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapy targeted to promote a systemic abscopal effect
JP2017528143A (ja) * 2014-09-10 2017-09-28 ザ ユニバーシティ オブ コネチカット 癌の治療のための免疫防御ネオエピトープ同定
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
EP3280738A4 (en) 2015-04-08 2019-01-02 Nantomics, LLC Cancer neoepitopes
AU2016253145B2 (en) * 2015-04-23 2020-07-02 Nant Holdings Ip, Llc Cancer neoepitopes
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
KR20180026670A (ko) * 2015-05-26 2018-03-13 어드박시스, 인크. 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도
WO2017011660A1 (en) * 2015-07-14 2017-01-19 Personal Genome Diagnostics, Inc. Neoantigen analysis
JP2018525002A (ja) * 2015-08-13 2018-09-06 チャンピオンズ オンコロジー インコーポレイテッド 疾患および障害の個別化された治療
KR20180087246A (ko) 2015-10-12 2018-08-01 난토믹스, 엘엘씨 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법
US11626187B2 (en) 2015-10-12 2023-04-11 Nantomics Llc Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
JP6710004B2 (ja) * 2016-03-15 2020-06-17 Repertoire Genesis株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
EP3933408A1 (en) * 2017-05-30 2022-01-05 Nant Holdings IP LLC Circulating tumor cell enrichment using neoepitopes
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
CA2797868C (en) * 2010-05-14 2023-06-20 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
AU2012261237B2 (en) * 2011-05-24 2017-06-01 BioNTech SE Individualized vaccines for cancer
LT2901341T (lt) 2012-09-28 2019-09-25 The University Of Connecticut Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui

Also Published As

Publication number Publication date
AU2013323368A1 (en) 2015-04-09
AU2013323368B2 (en) 2019-03-21
EP2901341A2 (en) 2015-08-05
WO2014052707A3 (en) 2015-05-14
EP2901341B1 (en) 2019-04-10
JP2015533082A (ja) 2015-11-19
JP2019058190A (ja) 2019-04-18
HRP20191182T1 (hr) 2019-10-04
US20150252427A1 (en) 2015-09-10
AU2019204354A1 (en) 2019-07-11
US10501801B2 (en) 2019-12-10
LT2901341T (lt) 2019-09-25
WO2014052707A2 (en) 2014-04-03
US20200017922A1 (en) 2020-01-16
JP6501708B2 (ja) 2019-04-17
ES2737757T3 (es) 2020-01-15
EP2901341A4 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
DK2901341T3 (da) Identifikation af tumorbeskyttelsesepitoper til behandling af cancere
IL288181A (en) Cancer treatment methods
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
IL241232A0 (en) Cancer treatment agents
DK3046583T3 (da) Viruslignende partikelkonjugater til behandling af tumorer
BR112014032105A2 (pt) método para o tratamento de câncer
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
EP2968348A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER
DK2785349T4 (da) Kombinationsbehandling af cancer
DK2717941T3 (da) Behandling af cancer
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
DK3305285T3 (da) Anti-androgener til behandlingen af ikke-metastatisk kastrationsresistent prostatakræft
DK3089749T3 (da) Kombinerede præparater til behandling af cancer
HK1214128A1 (zh) 癌症的治療
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
DK3077544T3 (da) Rationelt-baseret design af en målrettet terapi til cancer
DK3052102T3 (da) Sammensætninger til behandling af cancere
GB201217892D0 (en) Treatment of cancer
DK2892535T3 (da) Fremgangsmåde til adjuverende cancerbehandling
DK3290035T3 (da) Procaspase-kombinationsterapi til behandling af cancer